Literature DB >> 22689702

Clinical validity of the Mattis Dementia Rating Scale-2 in Parkinson disease with MCI and dementia.

Evelyne Matteau1, Nicolas Dupré, Mélanie Langlois, Pierre Provencher, Martine Simard.   

Abstract

The utility of the Mattis Dementia Rating Scale 2 (MDRS-2) in screening for dementia in Parkinson disease (PD) is well documented. However, little is known about its sensitivity to mild cognitive impairment in PD (PD-MCI). This study sought to document the validity of the MDRS-2 for diagnoses of PD-MCI and dementia in PD (PDD). Twenty-two healthy controls (HCs), 22 PD-MCI, and 16 PDD were compared on each MDRS-2 subscales and MDRS-2 total standard scores. Patients with PDD performed significantly worse than the other groups (all Ps < .05) on the MDRS-2 total and on all subscales, except attention. PD-MCI had significant lower scores than HCs on the MDRS-2 total and on initiation/perseveration and memory subscales. The optimal cutoff score for PD-MCI diagnosis was ≤ 140/144 and ≤ 132/144 for PDD. These findings suggest that MDRS-2 is a useful tool to identify dementia but that there might be a ceiling effect in the MDRS-2 cutoff score to diagnose MCI in PD.

Entities:  

Mesh:

Year:  2012        PMID: 22689702     DOI: 10.1177/0891988712445086

Source DB:  PubMed          Journal:  J Geriatr Psychiatry Neurol        ISSN: 0891-9887            Impact factor:   2.680


  21 in total

1.  DEVELOPMENT OF CLINICAL DEMENTIA RATING SCALE CUTOFF SCORES FOR PATIENTS WITH PARKINSON'S DISEASE.

Authors:  Kathryn A Wyman-Chick; B J Scott
Journal:  Mov Disord Clin Pract       Date:  2015-04-20

2.  The Movement Disorders Society criteria for the diagnosis of Parkinson's disease dementia: their usefulness and limitations in elderly patients.

Authors:  Michèle Kiesmann; Jean-Baptiste Chanson; Julien Godet; Thomas Vogel; Laetitia Schweiger; Saïd Chayer; Georges Kaltenbach
Journal:  J Neurol       Date:  2013-07-09       Impact factor: 4.849

Review 3.  Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests.

Authors:  Jeroen Hoogland; Lennard L van Wanrooij; Judith A Boel; Jennifer G Goldman; Glenn T Stebbins; John C Dalrymple-Alford; Connie Marras; Charles H Adler; Carme Junque; Kenn F Pedersen; Brit Mollenhauer; Cyrus P Zabetian; Paul J Eslinger; Simon J G Lewis; Ruey-Meei Wu; Martin Klein; Maria C Rodriguez-Oroz; Davide M Cammisuli; Paolo Barone; Roberta Biundo; Rob M A de Bie; Ben A Schmand; Alexander I Tröster; David J Burn; Irene Litvan; J Vincent Filoteo; Gert J Geurtsen; Daniel Weintraub
Journal:  Mov Disord       Date:  2018-09-14       Impact factor: 10.338

4.  Comparative sensitivity of the MoCA and Mattis Dementia Rating Scale-2 in Parkinson's disease.

Authors:  Taylor R Hendershott; Delphine Zhu; Seoni Llanes; Cyrus P Zabetian; Joseph Quinn; Karen L Edwards; James B Leverenz; Thomas Montine; Brenna Cholerton; Kathleen L Poston
Journal:  Mov Disord       Date:  2018-12-10       Impact factor: 10.338

Review 5.  Therapeutic development paths for cognitive impairment in Parkinson's disease: report of a regulatory roundtable.

Authors:  Jamie Eberling; Lona Vincent; Jennifer G Goldman; Daniel Weintraub; Jaime Kulisevsky; Connie Marras; Glenn Stebbins; Karl Kieburtz
Journal:  J Parkinsons Dis       Date:  2014       Impact factor: 5.568

6.  Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study.

Authors:  Hee Kyung Park; Sindana Ilango; Christina M Charriez; Harvey Checkoway; David Riley; David G Standaert; Yvette Bordelon; David R Shprecher; Stephen G Reich; Deborah Hall; Benzi Kluger; Connie Marras; Joseph Jankovic; Richard Dubinsky; Irene Litvan
Journal:  Mov Disord       Date:  2018-02-20       Impact factor: 10.338

7.  APOE, MAPT, and COMT and Parkinson's Disease Susceptibility and Cognitive Symptom Progression.

Authors:  Kimberly C Paul; Rebecca Rausch; Michelle M Creek; Janet S Sinsheimer; Jeff M Bronstein; Yvette Bordelon; Beate Ritz
Journal:  J Parkinsons Dis       Date:  2016-04-02       Impact factor: 5.568

8.  Longitudinal study of normal cognition in Parkinson disease.

Authors:  Kara Pigott; Jacqueline Rick; Sharon X Xie; Howard Hurtig; Alice Chen-Plotkin; John E Duda; James F Morley; Lama M Chahine; Nabila Dahodwala; Rizwan S Akhtar; Andrew Siderowf; John Q Trojanowski; Daniel Weintraub
Journal:  Neurology       Date:  2015-09-11       Impact factor: 9.910

9.  Altered Inhibitory Mechanisms in Parkinson's Disease: Evidence From Lexical Decision and Simple Reaction Time Tasks.

Authors:  Alban Letanneux; Jean-Luc Velay; François Viallet; Serge Pinto
Journal:  Front Hum Neurosci       Date:  2021-04-26       Impact factor: 3.169

10.  Accuracy of Two Cognitive Screening Tools to Detect Mild Cognitive Impairment in Parkinson's Disease.

Authors:  Emmie W Koevoets; Ben Schmand; Gert J Geurtsen
Journal:  Mov Disord Clin Pract       Date:  2018-03-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.